A Database-Derived Global Overview of HCV Resistance-Associated Substitutions: Characterizing Genotypic, Regional, and Temporal Heterogeneity

International Journal of Molecular Sciences 2026 Open access

Read full text
Authors: Gabriela Tavares Marinho Nunes, Thaís Barbosa Ferreira Sant’Anna, Natalia Motta Araujo
DOI: 10.3390/ijms27115068
Cited by: 1
References: 36

Abstract

Direct-acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) therapy, yet resistance-associated substitutions (RASs) remain a concern in specific clinical contexts. Here, we present a database-derived global overview of HCV RASs by analyzing 19,449 publicly available sequences across multiple genotypes and subtypes, encompassing both untreated and previously treated infections, in the NS3, NS5A, and NS5B genomic regions. We demonstrate a markedly heterogeneous distribution of RASs shaped by viral genotype, geographic origin, and treatment era. Importantly, RASs against pan-genotypic NS3 protease inhibitors (glecaprevir and voxilaprevir) were rare (generally

Fields of Study & Subjects

Hepatitis C virus research HIV/AIDS drug development and treatment Pharmacogenetics and Drug Metabolism

Publication details

Journal / source
International Journal of Molecular Sciences
Publisher
MDPI AG
Volume
27
Issue
11
Pages
5068–5068
Publication date
3 June 2026
Language
EN